Search

Angiogenesis plays a key role in the development and dissemination of colorectal cancer. In advanced stages this malignancy has a poor prognosis due to the inefficacy of the existent treatment and at this point the outcome cannot be completely predicted by common prognostic factors such as lymph node involvement, tumor size or local extension of the disease. For the management of these patients, a vast number of studies about appropriate biomarkers have been reported and they have been classified into prognostic biomarkers, predictive biomarkers, pharmacodynamic biomarkers and surrogate endpoints. The evaluation of prognostic biomarkers using immunohistochemistry, is increasingly used in the histopathologic diagnosis, having the potential to predict responsiveness to standard chemotherapy or novel molecular targeted therapy. The aim of this article is to address current immunohistochemical angiogenesis-based prognostic markers for patients with colorectal cancer, to summarize their current state and to discuss future perspectives. [ABSTRACT FROM AUTHOR]